Master One Thing - Rapamycin Longevity Series cover image

Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging

Master One Thing - Rapamycin Longevity Series

00:00

Phase 2 Vaccine Trial and Results

Joan reports low/intermittent rapalog dosing was safe and improved flu vaccine antibody responses in older adults.

Play episode from 29:26
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app